(688189)"Hunan Nucien Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688189 · · 15 pages · Chinese
Summary by 6ix AI
The report highlights significant changes in financial metrics, including a notable increase in revenue due to higher sales volumes from selected products. It also mentions a decrease in research and development expenditures as the company prepares for upcoming projects.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Hunan Nucien Pharmaceutical Co. Ltd. on 6ix
Earlier from Hunan Nucien Pharmaceutical
- (688189)"Hunan Nucien Pharmaceutical Co., Ltd."Indicative Announcement on Change in Equity Interests of Shareholder Holding More Than 5% of the Shares Reaching 1% Threshold
- (688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Amendment to the Articles of Association, Change of Legal Representative and Completion of Industrial and Commercial Registration Changes
- (688189)"Hunan Nucien Pharmaceutical Co., Ltd."Announcement on Temporary Use of Certain Idle Raised Funds to Supplement Working Capital
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
- Announcement on Election of New Board of Directors
Follow Hunan Nucien Pharmaceutical into a list and get an email when it puts out news.
Follow Hunan Nucien Pharmaceutical